Lawrence Saperstein, MD: Just 2 quick issues, if possible. By any new method in the depiction of this nature. There are 2 problems. One is the comfort level of the radiologist, who interprets the scans accurately and clearly, the other is the training of the referring physicians and their embrace of the new technology. These were high points and we are getting there, but these are two challenges in spreading the technology.
Neil Shore, MD, FACS: There is a line of study, there should definitely be training on how to interpret the images. What are the false positives and false positives? What is PSA? [prostate-specific antigen] measurements so that you get the most negative prediction value, positive findings? Michael, I think Stephen commented on academics and society. You now have a great deal of experience in both fields, and it has always been interesting to me that nuclear radiology colleagues like Dr. Saperstein are involved in the educational side, but how will this develop in a community setting? What was your experience in the field of academia and community experiences?
Michael Gorin, MD: When I was in John Hopkins, [Baltimore, Maryland,] we were very happy because Martin Pomper, MD, PhD, who is one of my mentors, was originally part of a team that led the team that developed the DCF PyL. [fluorine-18-DCFPyL] molecule. We had first-hand access to this radio tracker and with a large group. including Dr. Stephen P. Rowe, Muhammad E.. Allaf and Ashley Ross. We collected a portfolio of experiments that took advantage of our early access to this agent. And for several years now, virtually every patient who comes to Hopkins for their care has been recorded in a kind of imaging protocol, and we have had access to these results and were able to tailor their care based on it. When I moved to Urology Associates at UPMC West Maryland in Cumberland, there was a time when we didn’t have access to a PSMA image. Fortunately, we have a large imaging center here in advanced diagnostic radiology and we have access to OxyMon. Although very quickly, after FDA approval, Lantheus Medical Image, they were immediately logged in and entered our imaging site with access to PyL. And we now have access to this agent from a month or 2 months after its approval by the FDA and we have outstanding experience in ordering it. Our radiologist has done a good job of learning how to read scans in a short order, and this is partly because these are some incredibly clean scans that will last as long as you know what you’re looking for in a false positive way. are not. It was amazing. Now from January 1, we have full coverage of the radiotherapy and it is available to patients, especially if they are on Medicare. And from what I’ve seen about Lanteus, they’ve actually gone around the country, covering as many imaginative sites as possible. And just being very aggressive about handing it over to people in both the community and the training centers.
Neil Shore, MD, FACS: This is a high point and no doubt we have a group of Lantheus who are clearly trying to make sure that they are sufficiently feasible and nationally accessible. And on their heels will be Telix pharmaceuticals and their inaccessible products. And then, as you mentioned earlier, rhPSMA from Blue Earth Diagnostics and more are ahead. There are some interesting PSMA PETs that use copper. By having this more accessible and ultimately accessible, it only allows patients to receive an optimal diagnosis and then receive optimal treatment.
The transcript has been edited for clarity.